In this free webinar, gain insights into how to successfully navigate the regulatory framework for novel interventional agents. Attendees will understand agency expectations on the adequacy of information to support the conduct of clinical studies. Attendees will effectively manage unique safety considerations such as the timing of initial assessment to long-term follow up. The featured speakers will address the timing of efficacy endpoints assessment in early-phase vs late-phase clinical trials.
TORONTO, Oct. 4, 2023 /PRNewswire-PRWeb/ -- As the somatic cell and gene therapy platforms continue to advance, so do the US Food and Drug Administration (FDA) and international council for harmonisation of technical requirements for pharmaceuticals for human use (ICH) regulatory guidelines and the competent authority requirements associated with these product classes. Successful preclinical to clinical transition requires careful consideration of these agency guidance documents to minimize the risk of avoidable delays in the development of cell and gene therapy clinical trials in a regulated environment.
Many cell and gene therapy clinical trials come with their own challenges and have unique safety and efficacy considerations before they can be approved for marketing. Early-phase trials emphasize safety and have unique requirements regarding the timing of primary safety assessment. They often require lengthy long-term follow-ups. On the other hand, later phase trials, used to support a marketing application, require statistically significant and clinically meaningful efficacy data. Additionally, the development of novel appropriate endpoints is encouraged to showcase the effectiveness of these therapies.
This webinar will focus on best practices to navigate regulatory communications with the US FDA and how this guidance may inform pharma and biotech companies on the development of manufacturing, non-clinical development plans and investigational approaches.
Join this webinar to get insights on the US FDA guidelines and the managing of safety considerations and efficacy endpoints of these cell and gene therapy products.
Join experts from Emmes, Robert Anderson, PhD, Associate VP, Regulatory; and Kari Bingham, PharmD, CGT Safety Manager, Pharmacovigilance and Medical Monitoring, for the live webinar on Monday, October 16, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Cell and Gene Therapy Clinical Trials' Regulatory Strategies and Safety Considerations.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article